Demant: A Strong Player in the Growing Hearing Aid Market

Demant is a global leader in hearing healthcare and a key player in the market for hearing aids, diagnostic equipment, and hearing care services. Known for its strong brands such as Oticon and its global network of hearing care clinics, the company combines advanced technology with a vertically integrated business model that spans research and development, manufacturing, distribution, and direct patient care. With operations in more than 130 countries, continuous investment in innovation, and a growing presence in retail hearing care, Demant aims to expand its position as a full hearing healthcare provider while driving long term growth. The question remains: Does this hearing healthcare leader deserve a spot in your portfolio?

This is not a financial advice. I am not a financial advisor and I only do these post in order to do my own analysis and elaborate about my decisions, especially for my copiers and followers. If you consider investing in any of the ideas I present, you should do your own research or contact a professional financial advisor, as all investing comes with a risk of losing money. You are also more than welcome to copy me. 

For full disclosure, I should mention that I do not own any shares in Demant at the time of writing this analysis. If you would like to copy or view my portfolio, you can find instructions on how to do so here. If you want to purchase shares or fractional shares of Demant, you can do so through eToro. eToro is a highly user-friendly platform that allows you to get started on investing with as little as $50.

The Business

Demant was founded in Denmark and has grown into one of the world’s leading hearing healthcare companies, operating across hearing aids, hearing care services, and diagnostic solutions. The company operates a vertically integrated business model that spans research and development, manufacturing, distribution, and direct patient care through its global clinic network. This integrated structure allows Demant to control every step of the hearing healthcare journey, ensuring consistent quality, strong technological development, and operational efficiency. By overseeing both upstream activities such as product innovation and downstream activities such as patient interaction and servicing, the company maintains tight control over outcomes while benefiting from scale and coordination across the value chain. Demant’s core proposition is to provide advanced hearing solutions that improve quality of life for people with hearing loss, a large and structurally growing market driven by aging populations and increasing awareness. This positions the company within healthcare rather than discretionary spending, meaning demand is more resilient as hearing loss is a medical need that is typically addressed over time. The company sells its products and services through a global distribution network that includes operations in more than 130 countries, supported by both local sales organizations and external distributors, as well as a large and growing network of more than 4.500 hearing care clinics across over 25 countries. This combination of wholesale distribution and direct-to-consumer channels allows Demant to maintain strong market access while also building direct relationships with patients. Demant organizes its business into three primary segments that together cover the full hearing healthcare pathway. The Hearing Aids segment develops, manufactures, and sells hearing aids through a multi brand portfolio, addressing different customer segments and price points while focusing heavily on continuous innovation in areas such as sound processing and connectivity. The Hearing Care segment consists of the company’s global retail operations, where patients receive hearing tests, fittings, and ongoing care, creating a direct link between Demant and end users while also capturing retail margins. The Diagnostics segment includes audiometers, fitting solutions, and balance assessment equipment used by audiologists and ENT specialists, effectively positioning Demant at the starting point of the hearing care journey. A defining aspect of Demant’s business model is its ability to connect these three segments into a single ecosystem. Patients are often diagnosed using the company’s equipment, fitted with its hearing aids, and serviced through its clinics, creating a continuous relationship that can last for many years. This integrated approach allows Demant to benefit from repeat purchases, upgrades, and long term patient engagement, while also gathering valuable data that can be used to improve future products and services. The ability to combine technology, distribution, and direct patient interaction has helped Demant build a strong global position and deep expertise within audiology. Demant’s competitive moat is primarily built on its vertically integrated business model, technological expertise, and global distribution network. The vertically integrated structure is one of the company’s most important advantages, as it allows Demant to control the full value chain while creating a feedback loop between diagnostics, clinics, and product development. This leads to better products, improved patient outcomes, and higher customer retention, while also enabling the company to capture value at multiple points rather than relying solely on product sales. Another important competitive advantage lies in Demant’s investment in research and development. With significant annual spending and a large portfolio of patents, the company continuously improves its hearing solutions, which is critical in a market where performance and user experience drive purchasing decisions. This technological capability makes it difficult for smaller competitors to match the quality and innovation pace. Demant’s global distribution network further reinforces its competitive position. With thousands of clinics and a presence in more than 130 countries, the company has built a scale and reach that are difficult to replicate, allowing it to access a wide patient base while strengthening brand awareness and relationships with healthcare professionals. The company’s multi brand strategy also plays an important role, as it allows Demant to serve different segments and channels effectively, increasing market coverage while maintaining flexibility in pricing and positioning. The hearing healthcare industry itself is relatively concentrated, with a few large players dominating the market. In such a structure, companies that combine scale, innovation, and distribution tend to strengthen their positions over time. Demant’s ability to integrate its operations, leverage its global footprint, and continuously innovate allows it to compete effectively and gradually gain market share. These structural advantages support strong margins, recurring revenue from upgrades and services, and long term growth in a market that is both expanding and underpenetrated.

Management

Søren Nielsen serves as the CEO of Demant, a role he assumed in 2017 after more than two decades with the company. His appointment reflects Demant’s preference for internal leadership with deep industry expertise, as his entire career has been closely tied to the hearing healthcare sector. He holds a Master of Science in Industrial Management and Product Development from the Technical University of Denmark, where he initially studied Oticon as part of his thesis work, which ultimately led to his employment at the company in 1995. This early connection to the business has contributed to his strong understanding of both the technological and commercial aspects of hearing healthcare. Before becoming CEO, Søren Nielsen held a wide range of operational and leadership roles across the organization. Early in his career, he worked with Bernafon in Switzerland, where he played a key role in integrating the acquired hearing aid manufacturer into Demant’s multi brand structure. He later served in roles such as Quality Director and business unit leadership positions at Oticon, building experience across product development, operations, and organizational management. In 2008, he was appointed President of Oticon, taking responsibility for the company’s global hearing aid activities, which is the largest and most important business area within Demant. In 2015, he became Chief Operating Officer and Deputy CEO and joined the Executive Board, further expanding his oversight across the Group’s operations before ultimately being appointed CEO in 2017. Søren Nielsen has built a reputation as a leader with deep technical insight and a strong focus on execution. His background within engineering and product development gives him a detailed understanding of the technological drivers behind hearing aids, which is a key competitive factor in the industry. At the same time, his long tenure within Demant has given him a clear understanding of the company’s integrated business model, including the importance of connecting research and development, manufacturing, distribution, and direct patient care. This combination of technical expertise and operational experience allows him to make informed decisions across the entire value chain. Since becoming CEO, Søren Nielsen has overseen a strategic sharpening of the company’s focus on hearing healthcare. This includes divesting non core activities such as the audio and headset business and Oticon Medical, allowing Demant to concentrate fully on its core segments of hearing aids, hearing care, and diagnostics. This increased focus strengthens the company’s ability to allocate capital efficiently, accelerate innovation, and deepen its position within its core market. Under his leadership, Demant has also continued to expand its global hearing care network through acquisitions and new clinic openings, reinforcing its direct relationship with patients and strengthening its vertically integrated model. A central part of Søren Nielsen’s strategy has been maintaining strong investment in research and development, which is critical in a market where technological innovation drives product differentiation and long term competitiveness. At the same time, he has emphasized scalability and operational efficiency, ensuring that the company benefits from its global size while maintaining flexibility across its different business areas. His leadership approach combines a focus on long term value creation with a disciplined operational mindset, which is reflected in Demant’s ability to grow while maintaining strong margins. Beyond strategy and operations, Søren Nielsen places significant emphasis on company culture and employee development. With more than 26.000 employees globally, maintaining a strong organizational culture is essential for innovation and execution. He has consistently highlighted the importance of aligning the organization around a shared purpose while ensuring that employees have the resources and capabilities needed to deliver high quality solutions to patients. This focus supports both employee engagement and the company’s ability to innovate over time. Given his deep industry experience, long tenure within the company, and strong understanding of both technology and operations, Søren Nielsen appears well positioned to lead Demant through an increasingly competitive and technology driven healthcare landscape. His leadership aligns closely with the company’s strategy of focusing on core hearing healthcare activities, leveraging its integrated business model, and continuing to invest in innovation to strengthen its long term competitive position.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. Demant has consistently delivered ROIC above 10% over the past decade, with the clear exceptions of 2019, when an IT incident disrupted operations, and 2020, which was affected by the COVID pandemic. Outside of these unusual events, the company has demonstrated an ability to generate stable and attractive returns on capital, which is a strong indicator of a high-quality business. Several structural characteristics of Demant’s business model explain why the company has been able to maintain these levels of ROIC. First, Demant benefits from its vertically integrated operating model. The company controls research and development, manufacturing, distribution, and direct patient care through its clinic network. This allows Demant to capture value across multiple stages of the value chain rather than relying solely on product sales. It also creates a feedback loop where insights from diagnostics and clinics improve product development, leading to better products, higher patient satisfaction, and stronger demand. This integration supports both profitability and capital efficiency, which are key drivers of ROIC. Second, Demant operates in a market with favorable structural dynamics. Hearing loss is a medical need rather than a discretionary purchase, and demand is driven by aging populations and increasing awareness. This creates relatively stable and predictable demand over time. In addition, hearing aids require ongoing servicing and are typically replaced or upgraded over time, which generates recurring revenue without requiring large incremental investments in capital. This combination supports strong ROIC. Third, the company’s investment in research and development plays an important role. Demant continuously improves its products through innovation in sound processing, connectivity, and user experience. This differentiation supports adoption and pricing, which drives earnings. At the same time, the capital required for these innovations remains manageable relative to the level of profits generated, supporting attractive returns. Fourth, Demant’s distribution model contributes to its ROIC profile. The company combines wholesale distribution with a large and growing network of hearing care clinics. While the clinic network requires capital, it also allows Demant to capture retail margins and build direct relationships with patients, increasing lifetime value. Mature clinics tend to generate attractive returns, although newly acquired or newly opened clinics can dilute ROIC in the short term while they scale. The decline in ROIC in 2025 to around 10,9% appears to be driven more by timing and investment than by a structural deterioration in the business. Demant has been expanding its Hearing Care segment, including acquisitions such as KIND, and continues to invest in innovation and infrastructure. These initiatives increase the capital base and can temporarily reduce ROIC until they begin to contribute fully to earnings. Integration costs and short-term inefficiencies can also weigh on profitability during such periods. Looking ahead, ROIC is likely to remain above 10% and could gradually improve as recent investments mature. The underlying drivers of returns remain intact, including vertical integration, recurring demand, and technological differentiation. As the acquired clinics and other investments become more efficient and contribute more meaningfully to earnings, they should support higher returns. However, continued expansion and ongoing investment in research and development will likely keep ROIC from reaching significantly higher levels in the near term.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. Demant has generally managed to grow its equity over the past decade, although there have been a few years with declines. Overall, the trend is positive, with equity increasing from around DKK 7,0 billion in 2016 to roughly DKK 9,9 billion in 2025. This indicates that the company has consistently created value for shareholders over time, even if the growth has not been perfectly smooth year to year. One of the main drivers behind the increase in equity is consistent profitability. When Demant generates profits, a portion of those earnings is retained in the business, which increases equity. This is clearly visible in years where equity grows strongly, such as 2019, 2020, 2022, and 2023. Even in 2025, equity increased by about 3%, primarily driven by profit generation, although this was partly offset by other factors. This highlights that the underlying business remains profitable and continues to add value over time. At the same time, fluctuations in equity are often driven by capital allocation decisions rather than weakness in the business itself. Demant has historically returned capital to shareholders through share buybacks, which reduce equity because cash leaves the balance sheet. This is one of the key reasons why equity growth is not consistent every year. For example, years with negative equity growth, such as 2018 and 2021, can largely be explained by capital being returned to shareholders combined with temporary variations in earnings. Another important factor influencing equity is acquisitions. When Demant acquires other companies, it often uses cash or takes on debt to complete the transaction. This means that even though the company becomes larger, equity does not always increase right away. In fact, it can temporarily slow down equity growth. Over time, however, these acquisitions are expected to contribute to earnings, which will then support higher equity. So while acquisitions can create short term pressure on equity growth, they are typically made to strengthen the business and drive value over the long term. Currency movements also play a role. As a global company, Demant operates across many countries and currencies, and exchange rate fluctuations can impact the reported value of assets and equity. In 2025, currency translation had a negative effect on equity, partially offsetting the positive contribution from profits. These effects are typically accounting-related and do not reflect changes in the underlying business performance. The overall pattern shows that Demant is able to grow equity over time, but not in a straight line. This is typical for companies that both invest in growth and return capital to shareholders. The combination of steady profitability, strategic acquisitions, and shareholder returns leads to fluctuations in equity from year to year, even though the long-term direction remains positive. Looking ahead, equity is likely to continue increasing over time, but with some volatility. Demant operates in a growing market and generates consistent profits, which supports equity growth. However, continued investments in acquisitions, expansion of the clinic network, and share buybacks will likely create periods where equity growth slows or temporarily declines. As long as the company maintains strong profitability and allocates capital effectively, these fluctuations should not be a concern. Instead, they reflect an active capital allocation strategy aimed at balancing growth investments with returns to shareholders.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins provide a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share. Demant has historically generated solid free cash flow and attractive free cash flow margins. This reflects a business that is able to turn a meaningful portion of its earnings into cash, which is an important sign of quality. Over the past decade, free cash flow has generally trended upward, with some fluctuations, while margins have remained at healthy levels, often in the low to mid-teens. One of the main drivers of Demant’s strong free cash flow is its profitability. The company operates in a specialized healthcare market where technology, quality, and service matter more than price alone. This supports solid margins in its hearing aids business, while the Hearing Care segment allows the company to capture additional value through direct patient relationships. Because of this, a large share of revenue ultimately turns into operating profit and then into cash. Another important factor is that the business does not require extremely heavy investments relative to its size. While Demant does invest in production facilities, clinics, and research and development, these investments are still moderate compared to the cash generated by the business. This level of investment allows the company to grow while still generating strong free cash flow. Demant also benefits from recurring demand. Hearing aids need servicing and are typically replaced over time, and the company’s clinics maintain ongoing relationships with patients. This creates a steady flow of revenue and cash generation, rather than relying on one-time transactions. Over time, this recurring element supports consistent free cash flow margins. The fluctuations in free cash flow from year to year are mainly driven by investments and timing rather than structural changes in the business. For example, free cash flow declined in 2025 compared to the previous year, despite strong cash flow from operations. This was primarily due to higher investments and significant cash outflows related to acquisitions, including the purchase of KIND. While these reduce free cash flow in the short term, they are intended to support future growth and strengthen the company’s market position. Looking ahead, Demant is expected to remain a strong generator of free cash flow. The underlying drivers are still in place, including solid margins, recurring demand, and a business model that does not require excessive ongoing investment. Free cash flow may fluctuate depending on the level of acquisitions, expansion of the clinic network, and investments in production and innovation. However, as these investments mature and begin to contribute to earnings, they should support continued growth in free cash flow over time. Demant uses its free cash flow in a balanced way. First, the company reinvests in the business through research and development, expansion of its clinic network, and improvements to production and infrastructure. Second, it uses cash for acquisitions to strengthen its position in hearing care, as seen with the acquisition of KIND. Finally, excess cash is returned to shareholders, primarily through share buybacks. Management has stated that returning excess cash through buybacks remains a key part of its capital allocation strategy, as long as the company maintains a reasonable level of debt. The free cash flow yield suggests that Demant may be trading at its lowest valuation in more than a decade. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to consider is debt. It is crucial to assess whether a business has a manageable level of debt that can be repaid within a three-year period, calculated by dividing total long-term debt by earnings. Upon analyzing Demant, the company currently has around 6,9 years of earnings in debt, which is significantly higher than what I would usually prefer. However, this increase in debt is not due to weakness in the underlying business but rather a result of capital allocation decisions. Demant has increased its debt in recent years as it has allocated more capital to acquisitions, particularly in 2024 and 2025. Some of this activity was driven by postponed deals from 2023 being completed in 2024, while the acquisition of KIND in 2025 had a particularly large impact on debt levels. It is also important to note that Demant does not typically operate with this level of debt. Management has explicitly stated that the increase is temporary and that they intend to prioritize reducing debt going forward. At the end of 2025, the company’s debt level was above its normal target range, but management expects to bring it back down within 18 to 24 months. This indicates that the current level of debt is part of a deliberate strategy rather than a permanent change in the financial structure. Because the increase in debt is tied to acquisitions that are expected to strengthen the business and contribute to future earnings, the higher debt level does not necessarily reduce the investment case. However, it does introduce some short-term risk and makes it important to monitor how quickly the company is able to reduce debt. As long as Demant continues to generate strong cash flow and follows through on its plan to lower debt, this should not be a major concern. Still, I would prefer to see management prioritize debt repayment over the coming years.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Risks

Regulations is a risk for Demant because the company operates in a highly regulated healthcare industry where changes in rules can directly affect how products are developed, sold, and paid for. Unlike many other industries, hearing aids are classified as medical devices, which means they must meet strict safety, quality, and performance standards before they can be approved and sold. If regulatory authorities introduce new requirements, Demant may need to update product designs, adjust manufacturing processes, or strengthen testing and documentation. This can increase costs and, more importantly, delay the launch of new products. In a market where technological innovation is a key competitive factor, even small delays can reduce the impact of new product launches and give competitors an advantage. Another important regulatory risk relates to reimbursement schemes. In many countries, hearing aids are partly or fully paid for by governments or health insurance systems, which supports demand by making treatment more affordable. This is a key driver of market growth, especially among older patients who may otherwise delay treatment. However, if reimbursement levels are reduced, patients may have to pay more out of pocket. This can lead to lower demand, longer replacement cycles, or a shift toward cheaper products. As a result, Demant could face both slower growth and pressure on pricing. Because reimbursement systems differ across countries and are often influenced by political priorities and healthcare budgets, this adds an ongoing layer of uncertainty to the business. Public tenders are also an important part of the regulatory landscape. In some markets, governments or healthcare providers purchase hearing aids through large-scale tender processes, where suppliers compete to win contracts. These tenders often focus heavily on price, which can compress margins. If the rules around tenders change, for example by placing even greater emphasis on cost or by reducing the number of approved suppliers, it can make competition more intense. This could limit Demant’s ability to maintain pricing or even result in the loss of contracts in certain markets, which would directly impact revenue. Although the current regulatory environment is generally stable, the risk lies in the fact that changes can happen gradually and differ across markets. Governments are often under pressure to control healthcare costs, which increases the likelihood of reimbursement adjustments or stricter purchasing conditions over time. Even relatively small changes in reimbursement levels, product requirements, or tender structures can have a meaningful impact on profitability, especially when they affect multiple markets at once.

Competition is a risk for Demant because the company operates in a highly specialized industry with a limited number of large and well-established players, including Sonova and WS Audiology. These competitors have strong brands, significant research and development capabilities, and global distribution networks. As a result, competition is intense and largely driven by technology, product performance, and relationships with hearing care professionals and retailers. In such an environment, Demant must continuously invest in innovation to keep up with new product launches and maintain its competitive position. Management has also highlighted that the industry has seen a high number of product launches in recent periods, which increases competitive pressure and makes it more difficult to stand out. One of the most important competitive risks is pricing pressure. Because hearing aids are sold through both wholesale channels and large retail partners, competitors can compete aggressively on price to win contracts or gain market share. If competitors offer better pricing or more attractive terms, Demant may be forced to lower its own prices to remain competitive, which can reduce margins. This is particularly relevant in markets where large buyers, such as managed care organizations or retail chains, have strong negotiating power. As volumes become more concentrated among fewer large buyers, these customers gain leverage, which can push prices down across the industry. Another key risk is the reliance on large retail partnerships. Losing a major customer can have a meaningful impact on both revenue and market share. This has already been seen in the U.S., where Demant experienced a decline in market share due to lower sales to a large retailer after it expanded the number of suppliers. When retailers diversify their supplier base, competition increases, and no single company can rely on exclusive or dominant positions. This means Demant must continuously prove that its products offer the best combination of quality, technology, and value to retain these relationships. Competition is also increasing due to changes in distribution models. The industry has traditionally relied on audiologist-led channels, where hearing aids are prescribed and fitted by professionals. However, newer channels such as managed care programs, online sales, and over-the-counter hearing aids are becoming more important. While these channels can increase access to hearing care, they also introduce new competitors and often focus more on price and convenience. If competitors establish strong positions in these channels, Demant may find it more difficult to reach customers directly or maintain its pricing power. In addition, the retail side of the market is highly fragmented, with many independently owned hearing care clinics. This creates a competitive environment where strong relationships and brand recognition are important to attract customers. At the same time, consolidation among larger players and managed care organizations can shift bargaining power away from manufacturers like Demant and toward distributors and payers.

Macroeconomic factors is a risk for Demant because even though the company operates in a healthcare market with long-term structural growth, short-term demand can still be influenced by economic conditions. Hearing aids are often a necessary product, but they are not always urgent, which means patients can delay purchases during periods of uncertainty. In 2025, macroeconomic uncertainty led to slower-than-normal growth in the global hearing healthcare market, particularly in the U.S., as consumers postponed spending and clinics saw lower activity. This shows that even in a relatively resilient industry, demand can be affected when consumer confidence weakens. Another important factor is that Demant relies heavily on in-person interactions through its clinic network. A large part of the sales process involves testing, fitting, and counseling, which requires patients to physically visit clinics. When economic uncertainty increases, fewer people may prioritize these visits, leading to delayed diagnoses and treatment. This can slow down sales in the short term, even if the underlying need for hearing aids remains unchanged. Macroeconomic conditions also affect Demant through its Diagnostics business. Hospitals and clinics are key customers for diagnostic equipment, and their willingness to invest in new equipment is often tied to broader economic conditions. In 2025, macroeconomic uncertainty led to reduced investments in clinical and hospital equipment, particularly in the U.S., resulting in flat growth in this segment. This shows that parts of Demant’s business are more sensitive to economic cycles, especially when customers delay larger capital investments. In addition, global economic factors such as tariffs, inflation, and currency movements can impact profitability. Tariffs can increase the cost of selling products in certain markets, while currency fluctuations can affect both revenue and margins since Demant operates globally. Management has also noted that foreign exchange movements created a headwind for margins. At the same time, inflation can increase costs across the value chain, from production to distribution, which may be difficult to fully offset through pricing. Regional economic conditions also play a role. For example, weaker growth in markets such as China has acted as a drag on overall performance, showing that Demant is exposed to economic developments across multiple geographies. Because the company operates in more than 130 countries, it is affected by a wide range of local economic conditions, which adds complexity and variability to its performance.

Reasons to invest

Favorable structural trends is a reason to invest in Demant because the company operates in a market supported by long-term demand drivers that are largely independent of economic cycles. One of the most important of these drivers is the aging global population. As life expectancy increases, more people experience age-related hearing loss, which naturally expands the need for hearing healthcare solutions. The World Health Organization estimates that one in five people already live with some degree of hearing loss, and that number is expected to grow significantly in the coming decades. Because hearing loss typically worsens over time, demand for treatment is not only growing but also recurring, as patients require ongoing care and replacement of devices. Another key structural driver is the large gap between people who need treatment and those who actually receive it. Today, less than 20% of people who could benefit from hearing aids are using them. This means that the market is significantly underpenetrated, leaving substantial room for growth even without relying on population increases. As awareness improves and access to hearing healthcare expands, more people are expected to seek treatment. This creates a long runway for growth, as Demant is not only benefiting from demographic trends but also from increasing adoption rates. Growing awareness of hearing health is also an important factor. Hearing loss is increasingly being recognized as a serious health issue, not just a minor inconvenience. Untreated hearing loss has been linked to reduced quality of life, lower workforce participation, and higher risks of conditions such as depression and cognitive decline. As a result, both individuals and healthcare systems are placing greater emphasis on early diagnosis and treatment. This shift encourages more people to seek help earlier, which increases demand for hearing aids and related services over time. Accessibility is improving as well. In many developed markets, reimbursement programs help reduce the cost for patients, making hearing aids more affordable. At the same time, technological advancements have made devices smaller, more discreet, and easier to use, which reduces the stigma that has historically been associated with wearing hearing aids. Together, these factors are helping to expand the addressable market and drive higher adoption rates. Emerging markets represent an additional growth opportunity. In regions such as China, adoption rates remain very low, with only a small percentage of diagnosed individuals receiving treatment. As incomes rise and healthcare infrastructure improves, more people are expected to gain access to hearing care. This provides a significant long-term opportunity for companies like Demant to expand their presence and capture new customers. Finally, the broader economic impact of untreated hearing loss supports continued focus on the sector. The global cost of untreated hearing loss is estimated to be extremely high, driven by healthcare costs, lost productivity, and reduced participation in education and employment. This creates an incentive for governments and healthcare systems to invest in hearing care solutions and promote earlier treatment. Over time, this should support both demand and market growth.

Innovation is a reason to invest in Demant because the company operates in an industry where technological development is a key driver of growth, differentiation, and pricing power. Hearing aids are becoming increasingly advanced, with users expecting better sound quality, improved connectivity, and more intuitive functionality. To remain competitive, companies must continuously improve their products, and Demant has demonstrated a strong commitment to research and development to stay at the forefront of this evolution.ant is well-positioned to maintain its leadership in the hearing aid industry. One of the clearest examples of this is the launch of Oticon Zeal, which represents a meaningful step forward in hearing aid design and functionality. The product combines a discreet in-ear form factor with features typically only found in larger devices, including strong sound performance, connectivity, and rechargeability. This is important because it directly addresses one of the main barriers to adoption, which is that many first-time users want a solution that is both effective and discreet. By offering a product that meets both needs, Demant is not only improving its competitive position but also expanding the overall market by attracting new users. Innovation at Demant is also closely tied to its ability to drive premiumization. New products like Oticon Zeal are positioned at higher price points and have so far been well received by both hearing care professionals and end users. This shows that customers are willing to pay more for better technology and improved user experience. As a result, innovation does not just support volume growth but also contributes to higher average selling prices and improved profitability. At the same time, new flagship products often lift sales across the broader portfolio by attracting attention and bringing new customers into the ecosystem. Another important aspect of Demant’s innovation strategy is its focus on platform development. The company builds advanced technology platforms that can be used across multiple products and form factors. This allows Demant to introduce new devices more efficiently and ensure that even lower-priced products benefit from improvements in sound processing and connectivity. For example, the same core technology behind premium products can be adapted to serve different customer segments, which helps the company maintain a competitive offering across its entire portfolio. Artificial intelligence is becoming an increasingly important part of hearing aid technology, and Demant is investing heavily in this area. Modern hearing aids use advanced algorithms to understand the surrounding sound environment and adjust automatically, improving the listening experience for users. These capabilities are still evolving, which means there is significant potential for further improvement. Continued progress in this area can lead to better outcomes for users, which in turn supports higher adoption and stronger customer satisfaction. Innovation also plays a role in expanding the addressable market. By improving design, comfort, and ease of use, Demant can lower the threshold for starting treatment. Products that are smaller, more discreet, and easier to use reduce the stigma historically associated with hearing aids and encourage earlier adoption. This is particularly important given that a large portion of people with hearing loss remain untreated today.

Expanding hearing care is a reason to invest in Demant because the company is increasingly strengthening its position in the part of the value chain that is closest to the end customer. While many competitors focus primarily on manufacturing hearing aids, Demant has made a clear strategic decision to build and expand a global network of hearing care clinics. This allows the company to control not only the product but also the patient relationship, which is a significant advantage in a market where trust, service, and long-term care play an important role. One of the most important examples of this strategy is the acquisition of KIND, which represents the largest expansion in Demant’s history. By adding around 650 clinics, Demant significantly strengthened its presence, particularly in Germany, where it now holds a leading position in hearing care. This acquisition not only increases the company’s scale but also improves its ability to reach more patients directly. With more than 4.500 clinics globally, Demant is building a platform that allows it to serve millions of people through its own channels rather than relying solely on third-party distributors. Expanding the clinic network is strategically important because it gives Demant direct access to patients throughout the entire hearing care journey. From initial diagnosis to fitting and follow-up care, the company can guide the process and influence product choice. This strengthens customer relationships and increases the likelihood that patients will choose Demant’s products. It also creates recurring revenue opportunities, as patients often return for adjustments, servicing, and eventual upgrades of their hearing aids. Another key benefit of this strategy is improved profitability. By owning the point of sale, Demant can capture retail margins in addition to manufacturing margins. While clinics require investment, mature clinics tend to generate attractive returns over time. The acquisition of established networks like KIND accelerates this process, as these clinics are already operational and can contribute to earnings relatively quickly. Management expects KIND alone to contribute meaningfully to earnings, which highlights the financial impact of expanding hearing care. The expansion also strengthens Demant’s competitive position. A larger clinic network increases brand visibility and makes it easier for the company to reach new customers. It also provides valuable insights into patient behavior and preferences, which can be used to improve products and services. This creates a feedback loop where better products drive more patients into clinics, and insights from clinics improve future innovation. In addition, the hearing care market remains fragmented, especially at the clinic level, with many independent operators. This creates opportunities for consolidation, where larger players like Demant can acquire smaller networks and integrate them into a broader platform. Over time, this can lead to increased scale, better efficiency, and a stronger market position.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 11,20, which is from 2025. I have selected a projected future EPS growth rate of 7%. Management expects 6% to 8% growth moving forward. Additionally, I have selected a projected future P/E ratio of 30, which is twice the growth rate. This decision is based on Demant's historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be DKK 76,24. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Demant at a price of DKK 38,12 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 3.973, and capital expenditures were 652. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 456 in our calculations. The tax provision was 734. We have 213 outstanding shares. Hence, the calculation will be as follows: (3.973 – 456 + 734) / 213 x 10 = DKK 199,58 in Ten Cap price.

The final calculation is called the Payback Time price. It is a calculation based on the free cash flow per share. With Demant's Free Cash Flow Per Share at DKK 15,59 and a growth rate of 7%, if you want to recoup your investment in 8 years, the Payback Time price is DKK 171,15.

Conclusion

I believe Demant is an intriguing company with strong management. Demant has built its competitive moat based on its vertically integrated business model, technological expertise, and global distribution network. The company has historically achieved high ROIC and strong free cash flow, and while there will be volatility along the way, both are expected to grow over the long term. Regulations is a risk for Demant because changes in product requirements, reimbursement policies, and public tender rules can increase costs, delay product launches, and put pressure on pricing. Since demand in many markets depends on government support, even small regulatory changes can reduce growth and impact profitability over time. Competition is a risk for Demant because it operates in a concentrated market with strong global players that compete on technology, pricing, and distribution. This creates pressure on margins and increases the risk of losing key customers or market share, especially as new channels and large buyers gain more negotiating power. Macroeconomic factors is a risk for Demant because economic uncertainty can lead patients to delay treatment and clinics or hospitals to postpone investments, which slows demand in the short term. At the same time, factors such as inflation, tariffs, and currency movements can increase costs and put pressure on margins across its global operations. Favorable structural trends is a reason to invest in Demant because the company operates in a growing market driven by aging populations, increasing awareness, and improving access to treatment. At the same time, low adoption rates and recurring demand for hearing care create a long runway for sustained growth over many years. Innovation is a reason to invest in Demant because continuous technological improvements drive both growth and pricing power in the hearing aid market. By developing advanced products like Oticon Zeal, Demant can attract new users, support higher prices, and strengthen its competitive position over time. Expanding hearing care is a reason to invest in Demant because its growing network of clinics gives it direct access to patients, allowing it to capture more value across the entire hearing care journey. This strengthens customer relationships, supports recurring revenue, and improves profitability while reinforcing its competitive position through scale and closer market access. I believe there are many things to like about Demant, and buying shares at the Ten Cap price of DKK 199 could be a good long term investment.

My personal goal with investing is financial freedom. It also means that to obtain that, I do different things to build my wealth. If you have some extra hours to spare each month, you can turn a few hours a week into a substantial amount of money in a few years. If you are interested to know how I do it, you can read this post.

I hope you enjoyed my analysis! While I can’t post about every company I analyze, you can stay updated on my trades by following me on Twitter. I share real-time updates whenever I buy or sell, so if you’re making your own investment decisions, be sure to follow along!

Some of the greatest investors in the world believe in karma, and in order to receive, you will have to give. If you appreciated my analysis and want to get some good karma, I would kindly ask you to donate a bit to ADEPAC. It is a charity I know first hand and I know they do a great job and have very little money. If you have a few Euros to spare, please donate here by clicking on the Paypal icon. Even one or two Euros will make a difference. Thank you.